A turning point for clinical research in China?

摘要

China is experiencing rapid transitions in health, and has a heavy burden of cardiovascular diseases, lung cancer, chronic obstructive pulmonary disease, and diabetes. However, prevention and treatment guidelines for many diseases in China have been developed from evidence generated in western populations, or even from expert opinion. In the Symposium on Vision for Clinical Research in Next Ten Years & The Lancet Symposium at the China Heart Congress 2013, both western and Chinese participants shared the concern that China remains a country that imports medical evidence, rather than exports it, because of insufficient robust clinical research and data. Many racial and ethnic populations in China have persistent and extensive health disparities; direct adoption of medical evidence from western countries will not meet the health needs of Chinese people.